PRELUDE THERAPEUTICS INC (PRLD) Stock Earnings & Estimates
USA - NASDAQ:PRLD - US74065P1012 - Common Stock
1.62 USD
+0.12 (+8%)
1.65 USD
+0.03 (+1.85%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 7M | -100.00% | 22.787M | 70.878M 211.05% | 117.09M 65.20% | 188.66M 61.12% | ||||||
| EBITDA YoY % growth | -122.22M -8.33% | -131.108M -7.27% | -137.942M -5.21% | -170.968M -23.94% | -185.985M -8.78% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -123.54M -8.62% | -132.277M -7.07% | -139.714M -5.62% | -132.855M 4.91% | -135.099M -1.69% | -145.146M -7.44% | -182.436M -25.69% | -123.716M 32.19% | -47.497M 61.61% | -10.367M 78.17% | 51.263M 594.49% | |
| Operating Margin | N/A | N/A | -1,995.91% | N/A | N/A | N/A | N/A | -542.92% | -67.01% | -8.85% | 27.17% | |
| EPS YoY % growth | -2.44 -0.83% | -2.03 16.80% | -1.69 16.75% | -1.41 16.66% | -0.97 30.89% | -0.83 14.24% | -1.22 -46.64% | -0.90 26.67% | -0.53 40.91% | -0.21 59.62% | 0.15 171.43% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.37 13.36% | -0.26 31.42% | -0.29 30.30% | -0.29 28.35% | -0.34 8.28% | -0.34 -31.51% | -0.28 3.48% | -0.25 13.54% | -0.27 20.90% | -0.30 11.90% | -0.30 -7.22% | -0.30 -20.08% |
| Revenue Q2Q % growth | -100.00% | -100.00% | N/A | N/A | N/A | N/A | N/A | N/A | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -31.438M 8.55% | -30.653M 9.39% | -36.009M 7.35% | -36.19M 0.29% | -36.37M -15.69% | -36.553M -19.25% | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.41 10.87% | -0.45 | 0.04 | 8.54% |
| Q1 2025 Q2Q % growth | -0.42 | -0.48 | 0.06 | 12.08% |
| Q4 2024 Q2Q % growth | -0.38 17.39% | -0.47 | 0.09 | 19.59% |
| Q3 2024 Q2Q % growth | -0.43 4.44% | -0.48 | 0.05 | 10.65% |
| Q2 2024 Q2Q % growth | -0.46 14.81% | -0.44 | -0.02 | -4.88% |
| Q1 2024 Q2Q % growth | -0.42 27.59% | -0.49 | 0.07 | 15.10% |
| Q4 2023 Q2Q % growth | -0.46 23.33% | -0.50 | 0.04 | 7.96% |
| Q3 2023 Q2Q % growth | -0.45 28.57% | -0.59 | 0.14 | 24.24% |
| Q2 2023 Q2Q % growth | -0.54 6.90% | -0.65 | 0.11 | 16.41% |
| Q1 2023 Q2Q % growth | -0.58 7.94% | -0.70 | 0.12 | 16.99% |
| Q4 2022 Q2Q % growth | -0.60 15.49% | -0.64 | 0.04 | 6.33% |
| Q3 2022 Q2Q % growth | -0.63 4.55% | -0.65 | 0.02 | 2.89% |
| Q2 2022 Q2Q % growth | -0.58 | -0.62 | 0.04 | 6.78% |
| Q1 2022 Q2Q % growth | -0.63 -34.04% | -0.66 | 0.03 | 4.98% |
| Q4 2021 Q2Q % growth | -0.71 -57.78% | -0.70 | -0.01 | -1.99% |
| Q3 2021 Q2Q % growth | -0.66 87.43% | -0.64 | -0.02 | -3.53% |
| Q2 2021 Q2Q % growth | -0.58 | -0.50 | -0.08 | -15.11% |
| Q1 2021 Q2Q % growth | -0.47 | -0.43 | -0.04 | -8.68% |
| Q4 2020 Q2Q % growth | -0.45 | -0.48 | 0.03 | 5.63% |
| Q3 2020 Q2Q % growth | -5.25 | -0.44 | -4.81 | -1,096.99% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | -3.22% | 11.26% |
| Revenue | N/A | N/A | N/A | N/A |